((自动化翻译由路透提供，请见免责声明 ))
9月24日 - ** 券商Leerink Partners将Regeneron 的评级从 "跑赢大盘 "下调至 "市场表现"，将目标价从1,175美元下调至1,077美元。
** 称下调评级的导火索是法院对该公司2毫克剂量版眼部护理药物Eylea的裁决
** 周一，西弗吉尼亚州的一名联邦法官称，REGN不能 (link) 立即阻止竞争对手安进公司 的生物仿制药Eylea在美国的销售。
** 经纪公司称，这一裁决为该公司在美国的药品特许经营前景带来了不确定性。
** REGN指控AMGN的生物仿制药Eylea侵犯了其数十项专利。
** Leerink称不能排除AMGN提前推出Eylea生物仿制药的可能性；AMGN已于上月获得FDA批准。
** 截至上次收盘，REGN 的股价年累计上涨约 24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.